


306240



CERTIFICATE OF COMPLIANCE WITH GOOD MANUFACTURING PRACTICE GUIDELINES

THE NATIONAL DRUG POLICY AND AUTHORITY ACT, CAP 206

Issued under Regulation 19(5) of the National Drug Policy and Authority (Licensing) Regulations, 2014

Certificate No. 253/GMP/2020

This is to certify that the drug manufacturing facility:

Name of facility: Egyptian International Pharmaceuticals Industries Company (EIPICO).

Physical address of facility: 10th of Ramadan city, Industrial Area BI-Egypt, P.O. Box 149 -10th - Egypt

Has been assessed by the Authority for compliance with the Good Manufacturing Practice Guidelines.

On the basis of the assessment carried out on **28th October 2020**, it is certified that the facility indicated on this certificate complies with Good Manufacturing Practice for dosage forms listed in Table 1 below.

Table 1: Approved lines

No.	Dosage Form	Category	Activities
1.	Tablets (Coated and Uncoated)	Non-Beta Lactam	Manufacture of Finished Pharmaceutical Product
2.	Hard Gelatin Capsules		
3.	Soft Gelatin Capsules		
4.	Creams, Ointments and Suppositories		
5.	Oral Liquids		
6.	Eye Ointments		
7.	Eye sterile Drops		
8.	Oral powder for suspension		
9.	Small Volume Parenterals-Powders-Lyophilized		
10.	Small Volume Parenterals-Solutions-Hormones		
11.	Small Volume Parenterals-Powders	Beta lactam (Cephalosporins)	
12.	Tablets (Coated & uncoated)	Beta lactam (Penicillins)	
13.	Hard Gelatin Capsules		
14.	Oral powder for suspension		

The responsibility for the quality of the individual batches of the drugs manufactured through this process lies with the manufacturer.

This certificate remains valid until **28th October 2023**. It becomes invalid if the activities or the categories certified change or if the facility is no longer considered to be in compliance with GMP.

Issue Date: 28th October 2020.

